Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, at 1:00 PM ET. Members of the management team will engage in a fireside chat, which can be accessed via the 'Events' page on Aclaris' website. The webcast will be archived for at least 30 days. Aclaris focuses on developing novel drug candidates for patients with immuno-inflammatory diseases and boasts a multi-stage portfolio powered by a strong R&D engine, addressing significant treatment gaps in this area.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced preliminary topline results from its Phase 2a study evaluating zunsemetinib for treating moderate to severe hidradenitis suppurativa (HS). The study, involving 95 patients across 19 sites, did not meet its primary endpoint of reduced inflammatory nodule/abscess count compared to placebo. Secondary efficacy endpoints were also unmet. Although zunsemetinib's safety profile was consistent with prior studies, notable treatment-emergent adverse events included dizziness (16.7%) and diarrhea (12.5%). Aclaris remains optimistic about zunsemetinib's mechanism of action and is looking forward to upcoming data from its Phase 2b rheumatoid arthritis study.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported its financial results for Q4 and the full year of 2022, highlighting a net loss of $27.6 million for Q4, up from $22.8 million in Q4 2021. Total revenue rose to $7.8 million in Q4, driven by $6.7 million in licensing revenue. For the full year, Aclaris recorded a net loss of $86.9 million, an improvement from $90.9 million in 2021. Revenue increased to $29.8 million, mainly due to licensing agreements, including $17.6 million from Eli Lilly. The company has $229.8 million in cash and equivalents, expected to fund operations through 2025. Upcoming milestones include topline data from clinical trials for zunsemetinib in hidradenitis suppurativa in March 2023.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company, will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. The event can be accessed via a webcast on the company’s website, where it will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, aiming to meet the needs of patients with limited treatment options. The company features a strong R&D pipeline exploring protein kinase regulation.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) provided a positive corporate outlook for 2023, highlighting key clinical milestones for their lead programs, zunsemetinib and ATI-1777. The company plans to release topline data for several trials, including rheumatoid arthritis and atopic dermatitis, in mid to late 2023. Aclaris is also progressing ATI-2138 for T cell-mediated diseases and ATI-2231 for oncology. An upcoming presentation at the J.P. Morgan Healthcare Conference on January 11 will further discuss the company’s developments. Aclaris aims to address unmet needs in immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) and Pediatrix Therapeutics have announced a license agreement allowing Pediatrix to develop, manufacture, and commercialize ATI-1777, a soft Janus kinase (JAK) 1/3 inhibitor, for atopic dermatitis in Greater China. Aclaris will receive a $5 million upfront payment and could earn up to $91 million in milestone payments, alongside tiered royalties on net sales. This partnership aims to address the unmet medical needs for patients in the region, enhancing the global potential of Aclaris’ drug development efforts.